Welcome to our dedicated page for Arrowhead Pharma news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Pharma stock.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) regularly issues news on its RNA interference (RNAi) pipeline, regulatory milestones, clinical data, and capital markets activity. This ARWR news page on Stock Titan aggregates those updates so readers can follow how the company’s gene-silencing therapeutics are progressing across cardiometabolic, obesity, and neurodegenerative indications.
Recent company announcements highlight approvals and regulatory actions for REDEMPLO (plozasiran), a small interfering RNA medicine targeting apoC-III for adults with familial chylomicronemia syndrome (FCS). Arrowhead has reported approvals for REDEMPLO in the United States, Canada, and China, as well as Breakthrough Therapy designation for investigational plozasiran in severe hypertriglyceridemia and ongoing Phase 3 trials in broader triglyceride disorders.
News items also cover interim clinical data for investigational obesity candidates ARO-INHBE and ARO-ALK7, which the company is studying for effects on visceral fat, total fat, liver fat, and body weight, including in obese patients with type 2 diabetes mellitus. Additional coverage includes the initiation of a Phase 1/2a study of ARO-MAPT for tauopathies such as Alzheimer’s disease, using a TRiM-based delivery system intended to reach the central nervous system after subcutaneous administration.
Investors and observers will also find Arrowhead’s press releases on public offerings of common stock, pre-funded warrants, and 0.00% convertible senior notes due 2032, as well as collaboration and licensing updates such as the agreement with Novartis for ARO-SNCA and arrangements involving Visirna Therapeutics and Sanofi in Greater China. Bookmark this page to review Arrowhead’s earnings-related 8-K references, conference participation, and ongoing disclosures about its RNAi programs and commercial activities.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced that on December 12, 2025 its board approved inducement equity grants for 78 new employees under NASDAQ Rule 5635(c)(4).
The grants entitle those employees, in aggregate, to receive up to 141,310 restricted stock units. The awards are outside the company’s stockholder-approved equity plans and vest annually over four years.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has dosed the first subjects in a Phase 1/2a study of ARO-MAPT, an RNA interference therapeutic targeting the MAPT gene for Alzheimer’s disease and other tauopathies.
ARO-MAPT uses Arrowhead’s TRiM™ delivery platform; preclinical non-human primate data showed blood-brain-barrier penetration and broad CNS knockdown after subcutaneous dosing. The study will test single and multiple doses in healthy volunteers and multiple doses in early Alzheimer’s patients, with initial data expected in second half of 2026. Presentation slides from RNA Leaders USA Congress 2025 are available on Arrowhead’s investor website.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced the FDA granted Breakthrough Therapy designation to investigational plozasiran as an adjunct to diet to reduce triglycerides in adults with severe hypertriglyceridemia (SHTG) (TG ≥ 500 mg/dL).
The company said there are limited treatment options for millions with SHTG. Arrowhead plans to complete the SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 studies in mid-2026 and intends to file a supplemental New Drug Application (sNDA) with the FDA by year-end 2026, then pursue additional global regulatory submissions.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will participate in multiple December 2025 conferences with investor and scientific presentations. Key events include Piper Sandler 37th Annual Healthcare Conference (Dec 2-4; fireside chat Dec 3, 10:30 a.m. ET), Evercore 8th Annual Healthcare Conference (Dec 2-4; fireside chat Dec 4, 10:00 a.m. ET), WCIRDC (Dec 4-6) with multiple presentations on plozasiran and FCS/acute pancreatitis topics, and the 7th Annual CNS Delivery Summit (Dec 9-11; TRiM platform talk Dec 10, 9:30 a.m. ET). Presenters include Norman Lepore, Rohit Loomba, Nihar Desai and Agnieszka Glebocka. Presentation materials and webcast links will be available on the company Events and Presentations page under Investors.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported fiscal year 2025 results for the year ended September 30, 2025 and announced multiple commercial and partnership milestones.
Key facts: FDA approved REDEMPLO (plozasiran) for familial chylomicronemia syndrome (FCS) after Phase 3 PALISADE showed -80% triglycerides; REDEMPLO is self-administered once every three months. Fiscal highlights: Revenue $829,448, operating income $98,346, net loss attributable to Arrowhead $(1,631), and total cash resources $781,524. Major deals: $200M upfront from Novartis, $300M milestones from Sarepta, and $130M upfront from Sanofi (Visirna sale).
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced it earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT) after reaching the second development milestone in the Phase 1/2 study of ARO-DM1 (SRP-1003) for type 1 myotonic dystrophy.
The milestone followed a drug safety committee review, authorization to dose escalate, and attainment of a pre-specified patient enrollment target. Arrowhead said it expects to receive the payment within 60 days. The company reported cohort 4 (6 mg/kg) accrual is nearly complete and plans to begin enrollment in cohort 5 (12 mg/kg) in Q1 2026.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced FDA approval of REDEMPLO (plozasiran) to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). REDEMPLO is the first FDA‑approved siRNA medicine for FCS and is administered by subcutaneous injection once every three months. The approval is based on Phase 3 PALISADE results showing a median triglyceride change of -80% versus -17% for pooled placebo and a lower numerical incidence of acute pancreatitis. REDEMPLO will be available in the U.S. before the end of the year, and Arrowhead is launching a patient support program and advancing commercial capabilities as it becomes a commercial‑stage company.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will host a webcast and conference call on November 25, 2025 at 4:30 p.m. ET to discuss fiscal year 2025 results for the period ended September 30, 2025. Investors can access a live audio webcast on the Events and Presentations page in the Investors section of the Arrowhead website. A replay will be available approximately two hours after the call ends. Analysts who wish to join the conference call must register in advance to receive a dial-in number and personalized PIN.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced participation in multiple November 2025 scientific and investor events. Key appearances include the AHA Scientific Sessions (Nov 7-10) with a moderated poster on zodasiran on Nov 10, 2:34 pm CST, multiple presentations at AASLD Liver Meeting (Nov 7-11) on fazirsiran data and imaging analyses on Nov 9, 8:00 am EST, a Jefferies Global Healthcare fireside chat on Nov 19, and a TD Cowen virtual fireside on Nov 24. Webcast and materials will be posted on the company Events and Presentations investor page.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced that its board approved inducement equity grants on October 24, 2025 for 84 new employees under NASDAQ Listing Rule 5635(c)(4).
The grants entitle the recipients, in aggregate, to receive up to 127,230 restricted stock units (RSUs). These awards are outside the company's stockholder-approved equity incentive plans and vest annually over a four-year period.